Search
Tirzepatide Treatment Options
A collection of 110 research studies where Tirzepatide is the interventional treatment. These studies are located in the United States . Tirzepatide is used for conditions such as Obesity, Overweight and Type 2 Diabetes.
73 - 84 of 110
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
Not Yet Recruiting
This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-related comorbidities (excluding type 2 diabetes mellitus).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/03/2025
Locations: KUR Research - Trinity @ Bessemer, AL Site Network, Bessemer, Alabama +19 locations
Conditions: Obesity and Overweight
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
Completed
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/22/2025
Locations: University of Alabama-The Kirklin Clinic, Birmingham, Alabama +111 locations
Conditions: Nonalcoholic Steatohepatitis
A Study of LY3841136 in Overweight and Obese Participants
Active Not Recruiting
The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/21/2025
Locations: Fortrea Clinical Research Unit, Daytona Beach, Florida +2 locations
Conditions: Obesity, Overweight
Emulation of the Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT)
Active Not Recruiting
This cohort study was initiated to emulate the design of the SURPASS-CVOT trial using observational analogues of the trial design components in a study based on insurance claims data.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
01/15/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Type 2 Diabetes
Anti-obesity Pharmacotherapy and Inflammation
Active Not Recruiting
This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment
Gender:
ALL
Ages:
Between 35 years and 60 years
Trial Updated:
01/08/2025
Locations: LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NO, New Orleans, Louisiana +1 locations
Conditions: Obesity
A Study of a Weight Loss Intervention in People With Endometrial Cancer
Recruiting
The researchers are doing this study is to find out whether tirzepatide and semaglutide are practical (feasible) for weight management and blood sugar control for endometrial cancer patients undergoing chemotherapy. The researchers will also look at participants' experience with the study drug, the safety of taking the study drug while receiving chemotherapy, and changes in weight, body fat composition, and blood pressure of participants.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations
Conditions: Endometrial Cancer
Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers
Recruiting
Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.
Gender:
FEMALE
Ages:
Between 40 years and 64 years
Trial Updated:
12/16/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas +1 locations
Conditions: Obesity, Breast Cancer Risk
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
Not Yet Recruiting
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
Gender:
ALL
Ages:
Between 19 years and 80 years
Trial Updated:
12/12/2024
Locations: Biomed Research Unit #90067-102, Los Angeles, California +16 locations
Conditions: Obesity and Overweight
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
Completed
The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in participants with type 2 diabetes (T2D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Fiel Family and Sports Medicine PC, Tempe, Arizona +31 locations
Conditions: Type 2 Diabetes, Diabetes Mellitus, Type 2
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
Completed
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Cahaba Research, Birmingham, Alabama +31 locations
Conditions: Obesity, Overweight
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
Recruiting
Obesity, affecting 40% of US adults and costing 173b annually, represents a significant health care burden (1). It is associated with increased risk for multiple chronic diseases including hypertension, type 2 diabetes (T2D), cardiovascular disease, and NAFLD, as well as cancer, osteoarthritis, and obstructive sleep apnea. The investigators plan to test the hypothesis that tirzepatide, a dual GLP/GIP agonist, improves metabolic health (insulin resistance and regional fat distribution and cardiov... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/02/2024
Locations: Clinical and Translational Research Unit, Palo Alto, California
Conditions: Obesity, Overweight and Obesity, Overweight
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
Recruiting
This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer. The study will also assess the safety and tolerability of tirzepatide, its feasibility based on discontinuation rates, and completion of treatment. Secondary objectives include evaluating 3-year invasive disease-free survival (IDFS) and distant relapse-free survival (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Trinitas Comprehensive Cancer Center, Elizabeth, New Jersey +6 locations
Conditions: Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
73 - 84 of 110